↓ Skip to main content

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy

Overview of attention for article published in Clinical Cancer Research, October 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#27 of 11,148)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
30 news outlets
blogs
3 blogs
twitter
54 tweeters
patent
1 patent
facebook
2 Facebook pages

Citations

dimensions_citation
114 Dimensions

Readers on

mendeley
164 Mendeley
Title
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy
Published in
Clinical Cancer Research, October 2017
DOI 10.1158/1078-0432.ccr-17-1439
Pubmed ID
Authors

Yulian Khagi, Aaron M. Goodman, Gregory A. Daniels, Sandip P. Patel, Assuntina G. Sacco, James M. Randall, Lyudmila A. Bazhenova, Razelle Kurzrock

Abstract

Purpose: Tumor mutational burden detected by tissue next-generation sequencing (NGS) correlates with checkpoint inhibitor response. However, tissue biopsy may be costly and invasive. We sought to investigate the association between hypermutated blood-derived circulating tumor DNA (ctDNA) and checkpoint inhibitor response.Experimental Design: We assessed 69 patients with diverse malignancies who received checkpoint inhibitor-based immunotherapy and blood-derived ctDNA NGS testing (54-70 genes). Rates of stable disease (SD) ≥6 months, partial and complete response (PR, CR), progression-free survival (PFS), and overall survival (OS) were assessed based on total and VUS alterations.Results: Statistically significant improvement in PFS was associated with high versus low alteration number in variants of unknown significance (VUS, >3 alterations versus VUS ≤3 alterations), SD ≥6 months/PR/CR 45% versus 15%, respectively; P = 0.014. Similar results were seen with high versus low total alteration number (characterized plus VUS, ≥6 vs. <6). Statistically significant OS improvement was also associated with high VUS alteration status. Two-month landmark analysis showed that responders versus nonresponders with VUS >3 had a median PFS of 23 versus 2.3 months (P = 0.0004).Conclusions: Given the association of alteration number on liquid biopsy and checkpoint inhibitor-based immunotherapy outcomes, further investigation of hypermutated ctDNA as a predictive biomarker is warranted. Clin Cancer Res; 23(19); 5729-36. ©2017 AACR.

Twitter Demographics

The data shown below were collected from the profiles of 54 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 164 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 164 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 59 36%
Other 23 14%
Student > Ph. D. Student 22 13%
Student > Doctoral Student 11 7%
Student > Master 11 7%
Other 18 11%
Unknown 20 12%
Readers by discipline Count As %
Medicine and Dentistry 65 40%
Biochemistry, Genetics and Molecular Biology 32 20%
Agricultural and Biological Sciences 18 11%
Pharmacology, Toxicology and Pharmaceutical Science 5 3%
Immunology and Microbiology 4 2%
Other 6 4%
Unknown 34 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 261. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2020.
All research outputs
#73,346
of 17,365,229 outputs
Outputs from Clinical Cancer Research
#27
of 11,148 outputs
Outputs of similar age
#2,355
of 286,054 outputs
Outputs of similar age from Clinical Cancer Research
#4
of 220 outputs
Altmetric has tracked 17,365,229 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,148 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,054 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 220 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.